Expressions of Galectin-3 and HBME-1 in Nodular Lesions of the Thyroid.
- Author:
Jung Wook CHOI
1
;
Beom Gyu KIM
;
Sung Jae CHA
;
Tae Jin LEE
;
Sung Jun PARK
;
Sung Il PARK
Author Information
1. Department of Surgery, College of Medicine, Chung-Ang University, Seoul, Korea. psjsurgery@hanmail.net
- Publication Type:Original Article
- Keywords:
Galectin-3;
HBME-1;
Thyroid;
Nodular lesion
- MeSH:
Adenoma;
Carcinoma, Papillary;
Diagnosis;
Diagnosis, Differential;
Galectin 3*;
Hyperplasia;
Immunochemistry;
Incidence;
Thyroid Gland*
- From:Journal of the Korean Surgical Society
2006;71(3):183-188
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Galectin-3 and HBME-1 have been recognized as useful markers for the diagnosis of the thyroid lesions. In this study, we investigated whether they have a diagnostic value for nodular lesions of the thyroid. METHODS: We investigated the galectin-3 and HBME-1 expressions in 14 nodular hyperplasias, 30 papillary carcinomas, 17 follicular adenomas and 8 follicular carcinomas with using immunochemistry. RESULTS: Galectin-3 was positive in 96.7% of the papillary carcinomas and this incidence was significantly higher (P=0.0001) than that of nodular hyperplasia, 7.1%. However, the galectin-3 expressions of follicular adenoma and follicular carcinoma were not significantly different. HBME-1 was positive in 50.0% of the follicular carcinomas and this incidence was significantly higher (P=0.0001) than that of follicular adenoma. CONCLUSION: Galectin-3 and HBME-1 may be useful markers to diagnose papillary carcinoma. Although HBME-1 contributes to differential diagnosis of follicular adenoma and follicular carcinoma, further study is required.
